Rheumatoid Arthritis Therapeutics: A Global Strategic Business Report
San Jose, California (PRWEB) February 16, 2010
Rheumatoid arthritis is a chronic, debilitating disease, affecting one to two percent of the world's population. It is the most common autoimmune disease, and the most difficult to treat among all autoimmune diseases. Notably, the disease occurs more commonly in women than men. It affects tens of millions of people the world over, with no known cause and no cure available. Rheumatoid arthritis has always been a core area of interest for drug development companies. Research continues to focus on the discovery and development of new drugs that provide better safety and efficacy over the existing therapies.
The United States dominates the world rheumatoid arthritis therapeutics market as stated by the new market research report on rheumatoid arthritis therapeutics. The US rheumatoid arthritis therapeutics sales are driven by an increasing number of patients receiving treatment, more number of patients progressing to anti-TNF rather than receiving or continuing to receive DMARD monotherapy, more patients receiving a combination of DMARDs and biologics, and shift of anti-TNF failure patients to non-anti-TNFs therapy. As treatment options increase with the introduction of newer biologics including Actemra, Cimzia and Simponi in the anti-TNFs class and Ofatumumab, Ocrelizumab and Belimumab in the non-anti-TNFs class, physicians and patients are likely to benefit with the option to switch from one to another therapy until optimal treatment regimen is established.
Latin America represents the fastest growing market for rheumatoid arthritis therapeutics. Nevertheless, other markets including the United States and Europe are also projected to grow dynamically as the incidence of rheumatoid arthritis increases, and diagnosis and treatment rates increase. However, a large part of growth would come from patients who progress from NSAIDs and DMARDs to biologic therapies.
The global market for rheumatoid arthritis therapeutics, particularly the biological drugs segment is highly consolidated. Though there are several players in this market, only a few compete for market share by offering a few anti-TNF and non-anti-TNF drugs. Key players profiled in the report include Abbott Laboratories Inc., Amgen Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Genentech Inc., Johnson & Johnson Services Inc., Schering-Plough Corporation, UCB S.A., and Wyeth, among others.
The report titled "Rheumatoid Arthritis Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, pipeline drugs, research & development, product introductions/applications, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Japan, Europe, Latin America and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Rheumatoid_Arthritis_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/